Therapeutic Intervention With Neuromodulation and Inverse Virtual Reality in Patients With Fibromyalgia

November 28, 2023 updated by: Alejandro Caña Pino, University of Extremadura

Physiological and Functional Effects of Therapeutic Intervention With Neuromodulation Suit With and Without Combination of Reverse Virtual Reality in Fibromyalgia Patients.

INTRODUCTION: Fibromyalgia is a chronic condition of generalised pain that entails significant limitations in daily and social life due to pain, fatigue, sleep disturbances and mood alterations. Rehabilitation programmes try to alleviate the symptoms and seek intervention methodologies that contribute to improving the quality of life and reduce the socio-economic cost. Innovation, technology and new neurophysiologically based therapeutic interventions are being integrated into rehabilitation clinics and although there are foundations and research into the potential benefits that can be obtained, research is still needed to determine intervention protocols that are more effective and efficient. The company XXX has state-of-the-art technology and equipment in order to be able to offer high quality and professional services in Extremadura and is motivated to participate in scientific, innovation and development projects in order to analyse and take advantage of the great potential of the equipment and thus offer it to society. OBJECTIVE: this project aims to compare the influence of the use of immersive virtual reality combined with Exopulse neuromodulation suits on patients with fibromyalgia. METHODOLOGY: a clinical trial is proposed with probabilistic random assignment in three groups, a control group (G1) in which patients will wear the suit on, but it will not emit any type of current. A suit group (G2), in which only the neuromodulation suit will be used, and an experimental group (G3) in which, in addition to the neuromodulation suit, virtual reality glasses will be used in full immersive mode. The variables to be analysed are: pain, postural stability, muscle activity, muscle oxygenation, thermographic distribution, heart rate variability, stress, anxiety. The acute effects will be analysed after one intervention session (pre-post intervention of one session) and the effects after a programme of 8 sessions. RESOURCES: The intervention equipment will be provided by the company and the assessment equipment by the research group.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Madrid, Spain
        • Alejandro Rubio Zarapuz

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age between 18 and 65 years.
  • Diagnosis of fibromyalgia at least 3 months in advance.
  • Minimum perceived pain intensity of 3/10 according to the Numeric Pain Rating Scale.

Exclusion Criteria:

  • Having received physiotherapy 4 weeks prior to data collection.
  • Personal Psychological Apprehension Scale (PPAS) score greater than 37.5.
  • Contraindication to the use of electrotherapy.
  • Use of opioid medication that may generate changes at the level of the Autonomic Nervous System.
  • Ineligibility to participate in the study for other reasons deemed appropriate by the investigators.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Control group (G1)
Control group (G1): in which the suit shall be switched on, but with the current of all electrodes at 0 mA.
The present study consists of a comparative, randomized, controlled and clinical trial conducted to explore and compare the acute and chronic effects a treatment session with the Exopulse Mollii Suit, a treatment session with the Exopulse Mollii Suit combined with VR and a training session have on a Fibromyalgia patient.
Other Names:
  • a treatment session with the Exopulse Mollii Suit combined with VR on a Fibromyalgia patient
  • a training session have on a Fibromyalgia patient
Experimental: Suit group (G2)
Suit group (G2): will only receive treatment with the neuromodulation suit at the intensity preset by the manufacturer and according to the assessment criteria. The duration of the treatment will be 1 hour. Exopulse Molly Suit with all 58 electrodes active with an intensity of 2 milliamperes (mA) and pulse width of 30 milliseconds (ms)
The present study consists of a comparative, randomized, controlled and clinical trial conducted to explore and compare the acute and chronic effects a treatment session with the Exopulse Mollii Suit, a treatment session with the Exopulse Mollii Suit combined with VR and a training session have on a Fibromyalgia patient.
Other Names:
  • a treatment session with the Exopulse Mollii Suit combined with VR on a Fibromyalgia patient
  • a training session have on a Fibromyalgia patient
Experimental: Suit + VR group (G3):
Suit + VR group (G3): the intervention on this group was carried out in the same way as the suit group. However, the session was different as the participant wore VR glasses besides wearing the suit for an hour. The patient sees the same room he is in and a person performing a series of exercises he must follow as indicated by the video by video and voice commands. As exercise are performed in a laying position the patient must stay in this position for the whole session.
The present study consists of a comparative, randomized, controlled and clinical trial conducted to explore and compare the acute and chronic effects a treatment session with the Exopulse Mollii Suit, a treatment session with the Exopulse Mollii Suit combined with VR and a training session have on a Fibromyalgia patient.
Other Names:
  • a treatment session with the Exopulse Mollii Suit combined with VR on a Fibromyalgia patient
  • a training session have on a Fibromyalgia patient
Experimental: Exercise group (G4):
Exercise group: The procedure carried out is the same as in the suit group, but the session performed was a 1-hour session of strength exercise carried out by a certified professional.
The present study consists of a comparative, randomized, controlled and clinical trial conducted to explore and compare the acute and chronic effects a treatment session with the Exopulse Mollii Suit, a treatment session with the Exopulse Mollii Suit combined with VR and a training session have on a Fibromyalgia patient.
Other Names:
  • a treatment session with the Exopulse Mollii Suit combined with VR on a Fibromyalgia patient
  • a training session have on a Fibromyalgia patient

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain intensity
Time Frame: 8 weeks
VAS (Visual analog scale)
8 weeks
Postural stability
Time Frame: 8 weeks
Baropodometric platform Namrol
8 weeks
Heart rate variability
Time Frame: 8 weeks
RS800CX monitor (Polar Inc., Kempele, Finland). The Kubios HRV software (v. 3.3)
8 weeks
Tissue oxygenation
Time Frame: 8 weeks
Oximeter. Moxy-3
8 weeks
Thermographic distribution
Time Frame: 8 weeks
Camera E85 24" LENS. TELEDYNE FLIR. FLIR E8-XT system
8 weeks
Muscle activity
Time Frame: 8 weeks
MDurance surface electromyography.
8 weeks
Level of depression and anxiety
Time Frame: 8 weeks
Depression Anxiety Stress Scale
8 weeks
Body composition
Time Frame: 8 weeks
Inbody 270
8 weeks
Respiratory variables (forced expiratory volume in 1 second (FEV1), 6 seconds (FEV6) and the ratio of both these values (FEV1/FEV6))
Time Frame: 8 weeks
To measure the following variables a spirometry test was conducted with a Vitalograph Asma1 spirometer
8 weeks
Cortical arousal
Time Frame: 8 weeks
Measured trough the Critical Flicker Fusion Threshold (CFFT) in a viewing chamber (Lafayette Instrument Flicker Fusion Control Unit Model 12021)
8 weeks
Functional test
Time Frame: 8 weeks
chair stand test
8 weeks
Functional test
Time Frame: 8 weeks
Handgrip strength test
8 weeks
Functional test
Time Frame: 8 weeks
10m up and go test
8 weeks
Functional test
Time Frame: 8 weeks
One leg balance
8 weeks
Pressure pain threshold
Time Frame: 8 weeks
The algometer used was a Wagner FPKTM algometer with a blunt rubber tip of 1cm. The lateral epicondyle (2 cm distal to the epicondyles), and the inside of the knee (at the medial fat pad proximal to the joint line)
8 weeks
Salivary Biomarkers
Time Frame: 8 weeks
Unstimulated whole saliva was collected at rest and after exercise for each participant by direct draining into an ice-cold collection tube (pre-weighted) for 3 min After saliva collection, tubes with the samples were weighted (for saliva flux evaluation, mL/min), centrifuged at 1500× g for 10 min to remove food and cell debris, and the supernatant was stored at -20 ◦C until analysis
8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 20, 2022

Primary Completion (Actual)

January 19, 2023

Study Completion (Actual)

March 30, 2023

Study Registration Dates

First Submitted

January 19, 2023

First Submitted That Met QC Criteria

February 9, 2023

First Posted (Actual)

February 13, 2023

Study Record Updates

Last Update Posted (Actual)

December 4, 2023

Last Update Submitted That Met QC Criteria

November 28, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe